Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Trial of ZX008 (Fintepla) in Rare Seizure Disorders
2024-515680-61-00Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, Lennox-Gastaut syndrome (LGS) and epileptic encephalopathy, sponsored by Zogenix, Inc. Primary endpoint: Safety endpoints. Started Sep 2024; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epileptic encephalopathy
Beyond the preview
Go deeper on 2024-515680-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515680-61-00.